Day: September 15, 2025

All amounts are in United States dollars, unless otherwise stated. TORONTO, Sept. 14, 2025 (GLOBE NEWSWIRE) — Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (together with its direct and indirect subsidiaries, “Alamos” or the “Company”) today announced that its wholly owned Netherlands subsidiaries, Alamos Gold Holdings Coöperatief U.A. and Alamos Gold Holdings B.V. (the “Netherlands Subsidiaries”), have entered into a definitive agreement to sell Doğu Biga Madencilik Sanayi ve Tic. A.Ş., their wholly owned Turkish subsidiary, which owns the Kirazlı, Ağı Dağı and Çamyurt projects located in northwestern Türkiye, to Tümad Madencilik Sanayi ve Ticaret A.Ş (“Tümad”), a mining company operating in the Republic of Türkiye, for total cash consideration of $470 million (the “Purchase Price”) (the “Transaction”). The Purchase Price is payable by...

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FF Officially Started the Spinoff Plan for the Crypto Flywheel, a Second Independently Listed Company, to be Named CXC10Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FF Officially Started the Spinoff Plan for the Crypto Flywheel, a Second Independently Listed Company, to be Named CXC10The Company’s 919 event is just 5 days away. Company updates will be given at the 919 event including details on C10 & C (Crypto), the Company’s three growth engines, including the C10 Treasury; its roadmap for capital value realization; and the deployment strategy for FF EAI Vehicle Chain products.LOS ANGELES, Sept. 14, 2025 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”),...

NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercial launch of Ryoncil® (remestemcel-L-rknd), the only mesenchymal stromal cell (MSC) product approved by the United States Food and Drug Administration (FDA), was highlighted this past week in presentations at the Morgan Stanley and Cantor Fitzgerald Annual Global Healthcare Conferences held in New York. Mesoblast Chief Executive Silviu Itescu reiterated the strong first quarter launch of Ryoncil® and product sales in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGvHD) as recently reported in the Company’s full year earnings and discussed the continued drive to onboard new sites and increase product...